BofA analyst Joanna Gajuk raised the firm’s price target on Tenet Healthcare (THC) to $180 from $165 and keeps a Buy rating on the shares after having hosted a fireside chat with Tenet’s leadership team, including the CEO and CFO, at the BofA Health Care Conference. The overall tone was “bullish” as the company remains steadfast in achieving its strategic goals, according to the analyst, who cites increased confidence in the estimates and higher peer multiples for the firm’s raised price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $190 from $175 at Truist
- Billions of dollars of Medicaid payments for hospitals delayed, WSJ reports
- Tenet Healthcare: Strong Performance and Growth Potential Justify Buy Rating Despite Lowered Price Target
- Tenet Healthcare price target raised to $189 from $183 at RBC Capital
- Tenet Healthcare price target raised to $230 from $217 at UBS